Neuroprotection by sildenafil: neuronal networks potentiation in acute experimental stroke

CNS Neurosci Ther. 2014 Jan;20(1):40-9. doi: 10.1111/cns.12162. Epub 2013 Aug 30.

Abstract

Aims: Sildenafil, a phosphodiesterase type 5 inhibitor, has been found to produce functional recovery in ischemic rats by increasing the cGMP level and triggering neurogenesis. The aim of this study was to investigate further sildenafil mechanisms.

Methods: Male Sprague-Dawley rats underwent middle cerebral artery occlusion and reperfusion, followed by intraperitoneal or intravenous treatment of sildenafil starting 2 h later. Behavioral tests were performed on day 1 or day 7 after reperfusion, while cerebral infarction, edema, Nissl staining, Fluoro-Jade B staining, and electron microscopy studies were carried out 24 h poststroke. The cGMP-dependent Nogo-66 receptor (Nogo-R) pathway, synaptophysin, PSD-95/neuronal nitric oxide synthases (nNOS), brain-derived neurotrophic factor (BDNF)/tropomyosin-related kinase B (TrkB), and nerve growth factor (NGF)/tropomyosin-related kinase A (TrkA) were measured.

Results: Sildenafil enhanced neurological recovery and inhibited infarction, even following delayed administration 4 h after stroke onset. Furthermore, sildenafil reduced the loss of neurons and modulated the expressions of the cGMP-dependent Nogo-R pathway. Moreover, sildenafil protected the structure of synapses and mediated the expressions of synaptophysin, PSD-95/nNOS, BDNF/TrkB, and NGF/TrkA.

Conclusions: Sildenafil produces significant neuroprotective effects on injured neurons in acute stroke, and these are mediated by the cGMP-dependent Nogo-R pathway, NGF/TrkA, and BDNF/TrkB.

Keywords: Neuronal network; Neuroprotection; Sildenafil; Stroke.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain-Derived Neurotrophic Factor / metabolism
  • Cell Survival / drug effects
  • Disks Large Homolog 4 Protein
  • GPI-Linked Proteins / metabolism
  • Infarction, Middle Cerebral Artery / drug therapy*
  • Infarction, Middle Cerebral Artery / pathology
  • Intracellular Signaling Peptides and Proteins / metabolism
  • Male
  • Membrane Proteins / metabolism
  • Myelin Proteins / metabolism
  • Nerve Growth Factor / metabolism
  • Nerve Net / drug effects
  • Nerve Net / physiology
  • Neurons / drug effects*
  • Neurons / physiology
  • Neurons / ultrastructure
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / therapeutic use*
  • Nitric Oxide Synthase Type I / metabolism
  • Nogo Receptor 1
  • Piperazines / administration & dosage
  • Piperazines / therapeutic use*
  • Purines / administration & dosage
  • Purines / therapeutic use
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, trkA / metabolism
  • Receptor, trkB / metabolism
  • Receptors, Cell Surface / metabolism
  • Recovery of Function / drug effects
  • Reperfusion Injury / drug therapy
  • Reperfusion Injury / pathology
  • Sildenafil Citrate
  • Stroke / drug therapy*
  • Stroke / pathology
  • Sulfones / administration & dosage
  • Sulfones / therapeutic use*
  • Synapses / drug effects
  • Synapses / ultrastructure
  • Synaptophysin / metabolism

Substances

  • Brain-Derived Neurotrophic Factor
  • Disks Large Homolog 4 Protein
  • Dlg4 protein, rat
  • GPI-Linked Proteins
  • Intracellular Signaling Peptides and Proteins
  • Membrane Proteins
  • Myelin Proteins
  • Neuroprotective Agents
  • Nogo Receptor 1
  • Piperazines
  • Purines
  • Receptors, Cell Surface
  • Rtn4r protein, rat
  • Sulfones
  • Synaptophysin
  • Syp protein, rat
  • Nerve Growth Factor
  • Sildenafil Citrate
  • Nitric Oxide Synthase Type I
  • Receptor, trkA
  • Receptor, trkB